“…ON-TARGETplus SMART Pool nontargeting (D-001810-10) and CHMP2A (L-020247-01) siRNAs were purchased from GE Healthcare. The following plasmids were obtained from Hartmut Land (University of Rochester Medical Center, Rochester, NY), Jay Morgenstern (Imperial Cancer Research Fund, London, UK), Bob Weinberg (Whitehead Institute for Biomedical Research, Cambridge, MA), Feng Zhang (Massachusetts Institute of Technology, Cambridge, MA), Brett Stringer (QIMR Berghofer Medical Research Institute, Brisbane, Australia), Christopher Vakoc (Cold Spring Harbor Laboratory, Cold Spring Harbor, NY), Noboru Mizushima (The University of Tokyo, Tokyo, Japan), Wesley Sundquist (University of Utah School of Medicine, Salt Lake City, UT), Konrad Buessow (Max Planck Institute for Molecular Genetics, Berlin, Germany), and Hemmo Meyer (University of Duisburg-Essen, Essen, Germany) through Addgene: pBabe-Hygro (#1765; Morgenstern and Land, 1990), lentiCas9-Blast (#52962; Sanjana et al, 2014), lentiCRISPRv2 (puro; #98290; Brett Stringer Lab), LRG (Lenti_sgRNA_EFS_GFP, #65656; Shi et al, 2015), pMXs-IP-EGFP-mATG5 (#38196; Hara et al, 2008), pMXs-IP-EGFP-ULK1 (#38193; Hara et al, 2008), pMXs-IP-EGFP-LC3 (#38195; Hara et al, 2008), pEGFP-VPS4-E228Q (#80351; Votteler et al, 2016), pQTEV-VPS28 (#34803; Büssow et al, 2005), and pmCherry-GAL3 (#85662; Papadopoulos et al, 2017). To generate pCDH1-CMV-MCS-SV40-Hygro, the puromycin resistance gene (BamHI–SalI [blunted] in pCDH1-CMV-MCS1-EF1-Puro; #CD510A-1; System Biosciences) was replaced to the hygromycin resistance gene (BanHI–ClaI [blunted]) from pBabe-Hygro.…”